Full-Time
Supply Chain Technician
Ember Life Sciences Inc.
11-50 employees
Real-time temperature tracking for pharma shipping
Compensation Overview
$75k - $85k/yr
Westlake Village, CA, USA
In Person
Bachelor's, Associate's
 Operations & Logistics (1) |
|---|
Get referred to Ember Life Sciences Inc.
See people who can refer or advise you
- The candidate must have 1–3 years of experience in electronics testing, technical assembly, production, or warehouse/distribution roles.
- The candidate must have a strong understanding of basic electronics or a background as an electronics technician is highly preferred.
- The candidate must be comfortable working in both laboratory and warehouse environments.
- An associate or bachelor's degree in a technical field is a plus.
- The role is not entry-level; ideal candidates have hands-on industry experience.
- The candidate must demonstrate attention to detail and the ability to follow procedures.
- The candidate must be able to think creatively and in a process-oriented manner and adapt to a startup culture.
- Perform bench testing of electronic products, including sensor setup, power-on testing, data output verification, and product shipping tests to validate performance in real-world shipping conditions.
- Conduct quality inspections of product assemblies following detailed work instructions.
- Identify and report any anomalies during testing and inspection.
- Prepare, package, and schedule outbound product shipments.
- Handle and transport inventory, including moving product pallets between testing and shipping areas.
- Support general warehouse activities such as picking, packing, shipping, and material handling.
- Assist with final assembly checks and fulfillment of subscription-based, high-tech medical transport units.
- A strong understanding of basic electronics or a background as an electronics technician is highly preferred.
- An associate or bachelor's degree in a technical field is a plus.
Ember Life Sciences provides temperature-control solutions for shipping temperature-sensitive pharmaceutical products. Its Ember Cube is a reusable cooling device that works with a cloud-based SaaS dashboard, using cellular radio and GPS to deliver real-time data on location, temperature, and humidity. A return-to-sender feature helps cut shipping waste by replacing single-use materials such as Styrofoam, ice packs, and cardboard. The company uses a subscription-based model, charging recurring fees for its platform and services. Its goal is to improve precision, control, and accuracy in temperature-sensitive pharma shipping, differentiating itself through integrated hardware and real-time visibility that supports a circular logistics approach.
Company Size
11-50
Company Stage
Series A
Total Funding
$27M
Headquarters
Westlake Village, California
Founded
N/A
Get referred to Ember Life Sciences Inc.
See people who can refer or advise you
Simplify's Take
What believers are saying
- Ember closed $27 million Series A on May 27, 2026, adding Amgen Ventures.
- Ember launched Cube 2 commercially on April 29, 2026, after Red Dot recognition.
- James Braithwaite joined as Chief Product Officer on August 11, 2026, strengthening execution.
What critics are saying
- Adoption hinges on Ember Cube 2 proving reliability across hospital and home-delivery workflows.
- Alfresa exclusivity concentrates Japan execution risk in one distributor and one market.
- Single-product cold-chain hardware faces commoditization; failure to scale deployments kills the company.
What makes Ember Life Sciences Inc. unique
- Ember Cube 2 combines reusable packaging, GPS tracking, and temperature telemetry.
- Alfresa granted Ember exclusive Japanese healthcare sales rights on July 29, 2026.
- Ember leverages Ember Technologies’ temperature-control engineering, inherited from consumer products and design awards.
Help us improve and share your feedback! Did you find this helpful?
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%Ember LifeSciences has appointed James Braithwaite as Chief Product Officer to lead product strategy and development for its cold chain technology solutions. Braithwaite brings over 20 years of experience in engineering and product development. Most recently, he served as Chief Innovation Officer at SharkNinja, where he led global product development and helped expand the company's revenue from approximately $250 million to more than $6 billion. Previously, he was Head of Product Development at Dyson, contributing to growth from roughly $50 million to $2.5 billion over nine years. Braithwaite joins as Ember continues advancing its cold chain technology, including the Ember Cube, which won the 2026 Red Dot Design Award. The company aims to address the $35 billion in annual pharmaceutical industry losses from temperature excursions.
Alfresa Holdings said on July 30 that its core pharmaceutical wholesaling unit Alfresa has entered i…
Ember LifeSciences and Alfresa form strategic alliance to strengthen pharmaceutical cold chain in Japan. Thursday, July 30, 2026 Ember LifeSciences has entered into a capital and business alliance with Alfresa Corporation to enhance pharmaceutical cold chain logistics in Japan. As part of the agreement, Alfresa will invest in Ember through its Series A preferred stock and gain exclusive sales rights for Ember's healthcare cold chain solutions in the Japanese market. The partnership will focus on improving the quality of temperature-controlled pharmaceutical distribution, including the evaluation of the Ember Cube and related technologies for Alfresa's Home Care Delivery service. The service supplies specialty medicines directly from healthcare providers to patients' homes. Ember's Series A funding round also includes investments from Amgen, Cardinal Health, Carrier and Sea Court Capital. The new investment is expected to support Ember's business expansion while strengthening collaboration between the two companies. Ember develops pharmaceutical cold chain technologies that combine temperature-controlled transport with real-time shipment monitoring. Its Ember Cube 2 maintains temperatures between 2°C and 8°C for more than 72 hours while continuously tracking shipment conditions and location. The reusable container is also designed to reduce packaging waste compared with conventional single-use shipping solutions. Alfresa is Japan's largest pharmaceutical wholesaler by domestic net sales. The alliance supports its efforts to strengthen cold chain capabilities as demand for temperature-sensitive biopharmaceuticals and vaccines continues to increase.
Ember LifeSciences has entered into a capital and business alliance with Alfresa Corporation, a subsidiary of Alfresa Holdings Corporation and Japan's leading pharmaceutical wholesaler. The partnership aims to improve pharmaceutical cold chain logistics across Japan. As part of the alliance, Alfresa will invest in Ember's Series A preferred stock and obtain exclusive sales rights in Japan's healthcare sector for Ember's solutions. Other Series A investors include Amgen, Cardinal Health, Carrier and Sea Court Capital. Alfresa will evaluate the Ember Cube 2 and related technologies for its Home Care Delivery service, which delivers specialty pharmaceuticals directly to patients' homes. The Ember Cube 2 maintains temperatures between 2°C and 8°C for over 72 hours whilst monitoring shipment conditions and location in real time. The partnership addresses growing demand for precise cold chain logistics as temperature-sensitive biopharmaceuticals and vaccines increase.
Ember LifeSciences has raised $27 million in Series A funding, according to filings with the US Securities and Exchange Commission. Amgen Ventures participated in the round. The company launched as an offshoot of Ember Technologies, maker of the temperature control mug that has surpassed $500 million in total sales. Ember LifeSciences applies the parent company's proprietary temperature control technology to medicine distribution, aiming to improve transportation of life-saving medicines and vaccines globally. The company filed the notice under Regulation D of the Securities Act of 1933, which allows securities sales without registration. Clay Alexander serves as chief executive officer.